Bristol-Myers Squibb and Pfizer collaborate with Portola to develop andexanet alfa in Japan
Bristol-Myers Squibb and Pfizer have entered into a collaboration agreement with Portola Pharmaceuticals to develop and commercialize the investigational agent andexanet alfa in Japan. Andexanet alfa, which is in Phase 3 clinical development in the U.S. and Europe, is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban).
Click on this link for more information.
